DocuSign, Inc. (NASDAQ: DOCU), a provider of electronic signature software, Thursday said its first-quarter adjusted earnings more than tripled, aided by strong demand. Both profit and revenues exceeded the market’s projection.
First-quarter revenues advanced 58% annually to $469.1 million, which is well above experts’ prediction. The top-line benefitted from a strong performance by the core subscription business.
Adjusted earnings jumped to $0.44 per share from $0.12 per share last year. Market watchers were looking for a smaller bottom-line number. On an unadjusted basis, it was a net loss of $8.4 million or $0.04 per share, compared to a loss of $47.8 million or $0.26 per share in the first quarter of 2021.
DocuSign’s stock lost about 12% so far this year and is trading at a near one-year low. It closed Thursday’s regular session sharply lower.
Stocks you may like:
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated